Developing oncolytic viruses for clinical use: A consortium approach

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Oncolytic viruses represent a promising cancer therapy, selectively replicating within and destroying tumor cells.
• Viral infection triggers both virus-specific and tumor-specific immune responses, enhancing anti-cancer effects.
• Despite academic initiation, industry largely leads late-stage development and clinical trials, limiting comparative studies.

Purpose of the Study:

• To review the essential steps and considerations in the development and characterization of oncolytic viruses.
• To introduce a multidisciplinary academic consortium dedicated to oncolytic virus development.
• To outline the consortium's ambition to develop and evaluate a series of oncolytic viruses in diverse cancer types.

Main Methods:

• Literature review of oncolytic virus development and characterization.
• Description of a multidisciplinary academic consortium involving multiple Dutch universities.
• Outline of plans for developing and evaluating oncolytic viruses in preclinical and clinical settings.

Main Results:

• Oncolytic viruses possess a dual mechanism of action: direct tumor cell lysis and immune system activation.
• A significant gap exists in comparative preclinical and clinical studies evaluating different oncolytic viruses.
• A collaborative academic consortium has been established to address these development and evaluation challenges.

Conclusions:

• Oncolytic virus therapy holds significant potential for cancer treatment.
• Standardized development and comparative evaluation are crucial for advancing oncolytic virus therapies.
• The described academic consortium aims to contribute to the development of effective oncolytic virus treatments for various cancers.